Mihm Martin C, Mulé James J
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Translational Science, Melanoma Research and Treatment, Moffitt Cancer Center, Tampa, Florida.
Cancer Immunol Res. 2015 Aug;3(8):827-35. doi: 10.1158/2326-6066.CIR-15-0143.
In the past five decades, the role for lymphocytes in host immune response to tumors has been shown, at least in some patients, to be a critical component in disease prognosis. Also, the heterogeneity of lymphocytes has been documented, including the existence of regulatory T cells that suppress the immune response. As the functions of lymphocytes have become better defined in terms of antitumor immunity, specific targets on lymphocytes have been uncovered. The appreciation of the role of immune checkpoints has also led to therapeutic approaches that illustrate the effectiveness of blocking negative regulators of the antitumor immune response. In this Masters of Immunology article, we trace the evolution of our understanding of tumor-infiltrating lymphocytes and discuss their role in melanoma prognosis from the very basic observation of their existence to the latest manipulation of their functions with the result of improvement of the host response against the tumor.
在过去的五十年里,淋巴细胞在宿主对肿瘤的免疫反应中的作用已被证明,至少在一些患者中,是疾病预后的关键组成部分。此外,淋巴细胞的异质性也已被记录,包括存在抑制免疫反应的调节性T细胞。随着淋巴细胞在抗肿瘤免疫方面的功能得到更明确的界定,淋巴细胞上的特定靶点也被发现。对免疫检查点作用的认识还带来了治疗方法,这些方法证明了阻断抗肿瘤免疫反应负调节因子的有效性。在这篇《免疫学大师》文章中,我们追溯了我们对肿瘤浸润淋巴细胞认识的演变,并讨论它们在黑色素瘤预后中的作用,从对其存在的最基本观察到对其功能的最新操纵,结果是改善了宿主对肿瘤的反应。